Sanofi - American Depositary Shares (NQ:SNY)

41.60 -0.36 (-0.86%)

Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

43 44 Next >

UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease

October 20, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share ↗

October 17, 2026

Regeneron's biggest growth driver still has plenty of fuel left in the tank.

Via The Motley Fool

AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test

October 14, 2026

From Biotech Insider

Via GlobeNewswire

Sanofi-ADR (NASDAQ:SNY): A Dividend Quality Candidate with Solid Profitability ↗

August 27, 2026

Via Chartmill

Sanofi (NASDAQ:SNY) Screens as Undervalued Value Stock with Solid Profitability ↗

August 07, 2026

Via Chartmill

Sanofi-ADR (NASDAQ:SNY) Offers a High Dividend Yield With Strong Underlying Quality ↗

July 16, 2026

Via Chartmill

SANOFI-ADR (NASDAQ:SNY): A Decent Value Stock With Strong Fundamentals and an Undervalued Profile ↗

July 13, 2026

Via Chartmill

Sanofi-ADR (NASDAQ:SNY): A High-Yield Dividend Stock with Strong Fundamentals ↗

June 16, 2026

Via Chartmill

Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion ↗

October 01, 2026

Regeneron and Sanofi (NASDAQ:SNY) announced an expanded collaboration focused on developing next-generation medicines for type 2 inflammatory diseases, extending an alliance that has produced the...

Via MarketBeat

Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

October 01, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Is Regeneron Stock a Bargain Below $800? ↗

September 22, 2026

The past couple of years have been challenging for the company, but there is a light at the end of the tunnel.

Via The Motley Fool

Topics Intellectual Property

Sanofi Reviews Pipeline, Broadens Deal Hunt as It Rebuilds Research Engine ↗

September 22, 2026

Sanofi (NASDAQ:SNY) is reviewing its late-stage pipeline, broadening its business-development lens and working to rebuild early research output under new leadership, Chief Scientific Officer and Global...

Via MarketBeat

Sanofi Eyes €25B Dupixent Future, Expands M&A Hunt Ahead of Patent Loss ↗

September 20, 2026

Sanofi (NASDAQ:SNY) is prioritizing continued growth in Specialty Care while preparing for the loss of exclusivity of Dupixent in the early part of the next decade, according to Manuela Buxo, the...

Via MarketBeat

Topics Intellectual Property

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

September 08, 2026

Via Investor Brand Network

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

Via Investor Brand Network

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

Via Investor Brand Network

MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

Via Investor Brand Network

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

September 08, 2026

From BioMedWire

Via GlobeNewswire

Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? ↗

September 04, 2026

They could both outperform the market over the medium term, but one appears to have a clear edge.

Via The Motley Fool

Topics Intellectual Property

Sanofi Boasts a Dividend Yield of 5.4%, Trades Below 9x Earnings, and Just Got an FDA Win. Are Income Investors Missing a Rare Opportunity? ↗

August 26, 2026

The company has increased its dividend for 30 consecutive years.

Via The Motley Fool

Sanofi Q2 Earnings Call Highlights ↗

July 30, 2026

Sanofi (NASDAQ:SNY) raised its 2026 outlook after reporting double-digit second-quarter sales and earnings growth, driven by Dupixent, recently launched medicines and cost discipline. The company also...

Via MarketBeat

Topics Earnings

The Smartest Dividend Stock to Buy With $1,000 Right Now (Spoiler: It Yields 5.6%.) ↗

July 28, 2026

Add the effect of stock buybacks to the dividend, and you're looking at a total yield approaching 11%.

Via The Motley Fool

Topics Intellectual Property

Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities

July 21, 2026

EQNX::TICKER_START (OTCQB:AVAI),(NYSE:NVO),(NASDAQ:SNY),(NASDAQ:DXCM),(NASDAQ:TNDM) EQNX::TICKER_END

Via FinancialNewsMedia

3 High-Yield Dividend Stocks to Buy and Hold ↗

July 17, 2026

All three can be bought on the dip.

Via The Motley Fool

Topics Intellectual Property

2 Fast-Growing Pharmaceutical Stocks to Buy Now ↗

July 08, 2026

Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings.

Via The Motley Fool

Bargain Hunters: These 3 High-Yielding Stocks Recently Hit New 52-Week Lows ↗

June 30, 2026

These stocks pay between 5.3% and 6.7% in dividends.

Via The Motley Fool

Topics Intellectual Property

MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials

June 22, 2026

Via Investor Brand Network

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

June 22, 2026

Via Investor Brand Network

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

June 22, 2026

From BioMedWire

Via GlobeNewswire

Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now? ↗

May 25, 2026

The stock looks cheap, but appearances can be deceiving.

Via The Motley Fool

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

43 44 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.